Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome

HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS...

Full description

Saved in:
Bibliographic Details
Published inAIDS (London) Vol. 27; no. 13; pp. 2089 - 2099
Main Authors CHANG, Christina C, DORASAMY, Afton A, LEWIN, Sharon R, FRENCH, Martyn A, GOSNELL, Bernadett I, ELLIOTT, Julian H, SPELMAN, Tim, OMARJEE, Saleha, NARANBHAI, Vivek, COOVADIA, Yacoob, NDUNG'U, Thumbi, MOOSA, Mohamed-Yunus S
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 24.08.2013
Subjects
Online AccessGet full text

Cover

Loading…
Abstract HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification. Prospective, longitudinal cohort study for 24 weeks. Durban, South Africa. One hundred and thirty HIV-infected patients with first cryptococcal meningitis episode : Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis). Clinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement. Of 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P=0.026] and lower CSF protein (HR 0.53, P=0.059) prior to cART and lower CD4 T-cell increases (HR 0.99, P=0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n=51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n=55; 51.9%, HR 0.33, 0.33, and 0.12 and P=0.0003, 0.0042, and 0.0004, respectively). Persistent CSF cryptococcal growth at cART initiation and poor CD4 T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS.
AbstractList OBJECTIVEHIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification.DESIGNProspective, longitudinal cohort study for 24 weeks.SETTINGDurban, South Africa.PARTICIPANTSOne hundred and thirty HIV-infected patients with first cryptococcal meningitis episodeINTERVENTION: Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis).MAIN OUTCOME MEASUREClinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement.RESULTSOf 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P=0.026] and lower CSF protein (HR 0.53, P=0.059) prior to cART and lower CD4 T-cell increases (HR 0.99, P=0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n=51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n=55; 51.9%, HR 0.33, 0.33, and 0.12 and P=0.0003, 0.0042, and 0.0004, respectively).CONCLUSIONPersistent CSF cryptococcal growth at cART initiation and poor CD4 T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS.
HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification. Prospective, longitudinal cohort study for 24 weeks. Durban, South Africa. One hundred and thirty HIV-infected patients with first cryptococcal meningitis episode : Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis). Clinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement. Of 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P=0.026] and lower CSF protein (HR 0.53, P=0.059) prior to cART and lower CD4 T-cell increases (HR 0.99, P=0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n=51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n=55; 51.9%, HR 0.33, 0.33, and 0.12 and P=0.0003, 0.0042, and 0.0004, respectively). Persistent CSF cryptococcal growth at cART initiation and poor CD4 T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS.
Objective: HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral therapy (cART), mostly because of cryptococcosis-associated immune reconstitution inflammatory syndrome (C-IRIS). Identifying predictors of C-IRIS could enable risk stratification. Design: Prospective, longitudinal cohort study for 24 weeks. Setting: Durban, South Africa. Participants: One hundred and thirty HIV-infected patients with first cryptococcal meningitis episode Intervention: Antifungal therapy (amphotericin 1 mg/kg median 14 days, followed by consolidation and maintenance fluconazole) and cART (commenced median of 18 days from cryptococcal meningitis diagnosis). Main outcome measure: Clinical, blood, and cerebrospinal fluid (CSF) markers associated with C-IRIS before and during cART and clinical significance of CSF cryptococcal culture negativity pre-cART commencement. Results: Of 106 patients commencing cART, 27 (25.5%) developed C-IRIS, 16 (15.1%) neurological deterioration-not C-IRIS, and 63 (59.4%) no neurological deterioration. On multivariable analysis, C-IRIS was associated with persistent CSF cryptococcal growth [hazard ratio (HR) 0.27, P = 0.026] and lower CSF protein (HR 0.53, P = 0.059) prior to cART and lower CD4 super(+) T-cell increases (HR 0.99, P = 0.026) but not change in HIV viral load during cART. Using survival analysis, patients with a negative cryptococcal culture pre-cART commencement (n = 51; 48.1%) experienced fewer episodes of neurological deterioration, C-IRIS, and cryptococcal relapse/persistence than patients with culture positivity (n = 55; 51.9%, HR 0.33, 0.33, and 0.12 and P = 0.0003, 0.0042, and 0.0004, respectively). Conclusion: Persistent CSF cryptococcal growth at cART initiation and poor CD4 super(+) T-cell increases on cART are strong predictors of C-IRIS. Approaches aimed at achieving CSF culture negativity prior to cART should be evaluated as a strategy to reduce rates of C-IRIS.
Author MOOSA, Mohamed-Yunus S
DORASAMY, Afton A
NDUNG'U, Thumbi
ELLIOTT, Julian H
OMARJEE, Saleha
FRENCH, Martyn A
SPELMAN, Tim
CHANG, Christina C
GOSNELL, Bernadett I
COOVADIA, Yacoob
LEWIN, Sharon R
NARANBHAI, Vivek
Author_xml – sequence: 1
  givenname: Christina C
  surname: CHANG
  fullname: CHANG, Christina C
  organization: Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia
– sequence: 2
  givenname: Afton A
  surname: DORASAMY
  fullname: DORASAMY, Afton A
  organization: Department of Medical Microbiology, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital Academic Complex, South Africa
– sequence: 3
  givenname: Sharon R
  surname: LEWIN
  fullname: LEWIN, Sharon R
  organization: Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia
– sequence: 4
  givenname: Martyn A
  surname: FRENCH
  fullname: FRENCH, Martyn A
  organization: Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Australia
– sequence: 5
  givenname: Bernadett I
  surname: GOSNELL
  fullname: GOSNELL, Bernadett I
  organization: Department of Infectious Diseases, King Edward VIII Hospital, South Africa
– sequence: 6
  givenname: Julian H
  surname: ELLIOTT
  fullname: ELLIOTT, Julian H
  organization: Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia
– sequence: 7
  givenname: Tim
  surname: SPELMAN
  fullname: SPELMAN, Tim
  organization: Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia
– sequence: 8
  givenname: Saleha
  surname: OMARJEE
  fullname: OMARJEE, Saleha
  organization: HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
– sequence: 9
  givenname: Vivek
  surname: NARANBHAI
  fullname: NARANBHAI, Vivek
  organization: HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
– sequence: 10
  givenname: Yacoob
  surname: COOVADIA
  fullname: COOVADIA, Yacoob
  organization: Department of Medical Microbiology, National Health Laboratory Services, Inkosi Albert Luthuli Central Hospital Academic Complex, South Africa
– sequence: 11
  givenname: Thumbi
  surname: NDUNG'U
  fullname: NDUNG'U, Thumbi
  organization: HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa
– sequence: 12
  givenname: Mohamed-Yunus S
  surname: MOOSA
  fullname: MOOSA, Mohamed-Yunus S
  organization: Department of Infectious Diseases, King Edward VIII Hospital, South Africa
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27677637$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/23525034$$D View this record in MEDLINE/PubMed
BookMark eNqFkUuLFTEQhYOMOHdG_4FIbwQ3PVZSeXQvh-sTBkTQdZNOKhLpTu4k3Yv-97bOVcGNq6LgO3Woc67YRcqJGHvO4YZDb17fW38DI3AkFB1qLm3nH7EDlwZbpQy_YAcQum97NHDJrmr9DgAKuu4JuxSohAKUBzYdp5iis1Njk2_mzeUpf_u1nwr56JZcapND48p2WrLLzuUaa2trzS7ahXwT53lN1BRyOdUlLusSc2piCpOdZ7vrt6ZuyZc801P2ONip0rPzvGZf3739cvzQ3n16__F4e9c62YmlHVH1Co0OGjhZ1EJ0pDvD96c6gwhS9MJo60wIo1XaWyKHKIJXVgSkEa_Zq4e7p5LvV6rLMMfqaJpsorzWgZvdQaCU8H9U9mBAaZA7Kh9QV3KthcJwKnG2ZRs4DD8rGT7fvhn-rWSXvTg7rONM_o_odwc78PIM2LoHH4pNLta_nNHGaDT4AxKqmW8
CitedBy_id crossref_primary_10_1093_cid_ciac853
crossref_primary_10_1093_ofid_ofv194
crossref_primary_10_1111_myc_12977
crossref_primary_10_1093_ofid_ofad078
crossref_primary_10_1093_ofid_ofad158
crossref_primary_10_1111_myc_13467
crossref_primary_10_1016_S1473_3099_20_30771_4
crossref_primary_10_1080_14656566_2021_1940954
crossref_primary_10_1586_14787210_2015_1029917
crossref_primary_10_1007_s11910_019_0993_0
crossref_primary_10_1071_MA14030
crossref_primary_10_1186_s12920_021_00914_1
crossref_primary_10_1371_journal_ppat_1006207
crossref_primary_10_1097_QAD_0000000000000200
crossref_primary_10_1097_QCO_0000000000000224
crossref_primary_10_1093_ofid_ofv157
crossref_primary_10_3390_jof4040139
crossref_primary_10_1111_imj_15590
crossref_primary_10_1016_j_eimc_2017_11_002
crossref_primary_10_1016_j_mib_2017_10_018
crossref_primary_10_1038_s41572_023_00472_z
crossref_primary_10_1111_imr_12063
crossref_primary_10_1007_s11046_020_00512_2
crossref_primary_10_1093_infdis_jiy083
crossref_primary_10_1016_j_mycmed_2023_101364
crossref_primary_10_1128_mBio_00166_17
crossref_primary_10_1186_s12974_023_02717_w
crossref_primary_10_1186_1476_0711_12_40
crossref_primary_10_1093_ofid_ofy157
crossref_primary_10_1007_s11908_013_0378_5
crossref_primary_10_1093_infdis_jit271
crossref_primary_10_1111_imj_12597
crossref_primary_10_1186_1471_2334_14_423
crossref_primary_10_1016_S1473_3099_16_00074_8
crossref_primary_10_4269_ajtmh_20_0028
crossref_primary_10_1093_infdis_jit388
crossref_primary_10_1093_mmy_myv104
crossref_primary_10_1097_QAI_0000000000001946
crossref_primary_10_1111_myc_13361
crossref_primary_10_1128_AAC_01299_15
crossref_primary_10_1016_j_mmcr_2014_12_003
crossref_primary_10_1097_ID9_0000000000000044
crossref_primary_10_1186_s12981_022_00444_5
crossref_primary_10_3390_jof3020028
crossref_primary_10_1007_s11904_024_00691_3
crossref_primary_10_1007_s40588_015_0016_0
crossref_primary_10_3390_jof2010001
crossref_primary_10_3390_jof5020042
crossref_primary_10_1002_eji_201545689
crossref_primary_10_1093_ofid_ofz369
crossref_primary_10_1007_s40588_018_0099_5
crossref_primary_10_1097_CM9_0000000000001191
crossref_primary_10_3390_life11020095
crossref_primary_10_1093_cid_ciad123
crossref_primary_10_1093_cid_ciad122
crossref_primary_10_1093_ofid_ofx032
crossref_primary_10_1080_14787210_2017_1285697
crossref_primary_10_1093_cid_cix598
crossref_primary_10_1093_infdis_jiv067
crossref_primary_10_1016_j_idc_2014_05_002
crossref_primary_10_1016_j_idcr_2022_e01554
crossref_primary_10_3389_fmed_2023_1192086
crossref_primary_10_1093_cid_ciu641
crossref_primary_10_1007_s11904_014_0213_0
crossref_primary_10_3390_microorganisms10122419
crossref_primary_10_1016_j_diagmicrobio_2014_09_006
crossref_primary_10_1002_jia2_25416
crossref_primary_10_1093_infdis_jiy448
crossref_primary_10_1093_infdis_jiy447
crossref_primary_10_1016_j_clineuro_2024_108423
crossref_primary_10_1016_j_idc_2021_03_012
crossref_primary_10_1097_QAD_0000000000001796
crossref_primary_10_1016_j_jns_2021_117453
crossref_primary_10_1016_j_eimce_2017_11_024
crossref_primary_10_1038_s41598_020_67031_4
crossref_primary_10_1016_j_trsl_2015_07_010
crossref_primary_10_1056_NEJMoa1312884
crossref_primary_10_1007_s40475_015_0046_y
crossref_primary_10_1016_S1473_3099_23_00731_4
crossref_primary_10_3389_fmed_2021_626266
crossref_primary_10_1186_s12981_016_0126_7
crossref_primary_10_1089_aid_2017_0209
crossref_primary_10_1097_QCO_0000000000000315
crossref_primary_10_1097_COH_0000000000000109
crossref_primary_10_1007_s40588_016_0033_7
crossref_primary_10_1007_s40588_016_0035_5
crossref_primary_10_1016_j_jiac_2022_11_002
Cites_doi 10.1093/cid/cit019
10.1086/605497
10.1086/652652
10.1086/593194
10.5694/mja12.10089
10.1097/01.aids.0000174450.70874.30
10.1046/j.1468-1293.2000.00012.x
10.1097/QAI.0b013e3181a56f2e
10.1097/QAD.0b013e3283536a93
10.1086/503903
10.1097/QAD.0b013e328322ffac
10.1371/journal.pone.0010980
10.1086/655785
10.1086/657082
10.1086/599112
10.1086/587667
10.1093/cid/cir230
10.1111/imr.12063
10.1016/S0140-6736(04)16301-0
10.1086/604716
10.1097/01.aids.0000131375.21070.06
10.1056/NEJMoa1013911
10.1086/518607
10.1007/s12281-011-0064-8
10.1016/S1473-3099(10)70026-8
10.1097/00005792-200205000-00005
10.7326/0003-4819-80-2-176
10.1258/ijsa.2011.010538
10.1086/649858
10.1016/S1473-3099(10)70170-5
10.1097/QAI.0b013e318183181e
10.1056/NEJMoa1014181
ContentType Journal Article
Copyright 2014 INIST-CNRS
Copyright_xml – notice: 2014 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7T5
7U9
H94
M7N
DOI 10.1097/qad.0b013e3283614a8d
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Immunology Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
Algology Mycology and Protozoology Abstracts (Microbiology C)
DatabaseTitleList MEDLINE - Academic
MEDLINE
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1473-5571
EndPage 2099
ExternalDocumentID 10_1097_QAD_0b013e3283614a8d
23525034
27677637
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations South Africa
GeographicLocations_xml – name: South Africa
GrantInformation_xml – fundername: Howard Hughes Medical Institute
GroupedDBID ---
.GJ
.XZ
.Z2
01R
08R
0R~
1CY
1J1
23M
2WC
354
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
85S
8L-
AAAXR
AAGIX
AAHPQ
AAJCS
AAMOA
AAMTA
AAPBV
AAQKA
AARTV
AASOK
AASXQ
AAXQO
ABASU
ABBUW
ABDIG
ABFLS
ABIVO
ABXVJ
ABZAD
ACCJW
ACDDN
ACEWG
ACGFS
ACOAL
ACWDW
ACWRI
ACXNZ
ADBBV
ADFPA
ADNKB
AE3
AE6
AEBDS
AENEX
AFDTB
AFFNX
AFUWQ
AGINI
AHRYX
AHVBC
AIJEX
AJIOK
AJNYG
AKULP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AWKKM
BAWUL
BOYCO
BQLVK
BS7
BYPQX
C45
CAG
COF
CS3
DIK
DIWNM
DUNZO
E.X
E3Z
EBS
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FL-
FW0
GQDEL
H0~
HZ~
IKREB
IKYAY
IN~
IPNFZ
IQODW
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
N4W
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OBH
OCUKA
ODA
ODMTH
OHH
OHYEH
OJAPA
OK1
OL1
OLB
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
OPX
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
R58
RIG
RLZ
S4R
S4S
SJN
T8P
TEORI
TR2
TSPGW
UAP
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
XJT
XXN
XYM
YFH
ZGI
ZXP
ZZMQN
AAAAV
AAIQE
AAUEB
ABJNI
ACILI
ADGGA
ADHPY
AEETU
AFEXH
AHOMT
AHQNM
AINUH
AJNWD
AJZMW
AMNEI
CGR
CUY
CVF
ECM
EIF
FCALG
NPM
AAYXX
CITATION
7X8
7T5
7U9
H94
M7N
ID FETCH-LOGICAL-c482t-b3595376f601ea36228e687157187330429276ac7ffba56daeec332fd5a2f3eb3
ISSN 0269-9370
IngestDate Sat Aug 17 04:19:23 EDT 2024
Fri Aug 16 20:53:44 EDT 2024
Fri Aug 23 03:00:07 EDT 2024
Sat Sep 28 07:51:56 EDT 2024
Thu Nov 24 18:25:55 EST 2022
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 13
Keywords HIV/AIDS
Immunopathology
Nervous system diseases
Mycosis
cryptococcal meningitis
cryptococcosis-associated immune reconstitution inflammatory syndrome
Cryptococcosis
Retroviridae
Immune reconstitution
AIDS
Immune deficiency
Lentivirus
Infection
Virus
Immune reconstitution syndrome
Viral disease
Central nervous system disease
immune restoration disease
Meningitis
Human immunodeficiency virus
Predictive factor
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c482t-b3595376f601ea36228e687157187330429276ac7ffba56daeec332fd5a2f3eb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.1097/qad.0b013e3283614a8d
PMID 23525034
PQID 1490705604
PQPubID 23479
PageCount 11
ParticipantIDs proquest_miscellaneous_1735923440
proquest_miscellaneous_1490705604
crossref_primary_10_1097_QAD_0b013e3283614a8d
pubmed_primary_23525034
pascalfrancis_primary_27677637
PublicationCentury 2000
PublicationDate 2013-08-24
PublicationDateYYYYMMDD 2013-08-24
PublicationDate_xml – month: 08
  year: 2013
  text: 2013-08-24
  day: 24
PublicationDecade 2010
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: England
PublicationTitle AIDS (London)
PublicationTitleAlternate AIDS
PublicationYear 2013
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
References Perfect (R33-9-20210130) 2010; 50
Robertson (R5-9-20210130) 2006; 42
Bicanic (R17-9-20210130) 2009; 49
French (R18-9-20210130) 2000; 1
Bisson (R36-9-20210130) 2008; 49
Haddow (R7-9-20210130) 2010; 10
Muller (R3-9-20210130) 2010; 10
Bicanic (R30-9-20210130) 2007; 45
Bisson (R8-9-20210130) 2013; 56
Makadzange (R10-9-20210130) 2010; 50
Abdool Karim (R11-9-20210130) 2011; 365
Shelburne (R6-9-20210130) 2002; 81
Chang (R26-9-20210130) 2013; 254
Oliver (R27-9-20210130) 2010; 202
Kambugu (R28-9-20210130) 2008; 46
Diamond (R23-9-20210130) 1974; 80
Pappas (R32-9-20210130) 2009; 48
Sungkanuparph (R38-9-20210130) 2009; 49
Bicanic (R24-9-20210130) 2009; 51
French (R4-9-20210130) 2004; 18
Schutzer (R29-9-20210130) 2010; 5
Jarvis (R35-9-20210130) 2012; 26
Lortholary (R19-9-20210130) 2005; 19
Longley (R37-9-20210130) 2008; 47
Torok (R13-9-20210130) 2011; 52
Park (R1-9-20210130) 2009; 23
Blanc (R12-9-20210130) 2011; 365
Wiesner (R16-9-20210130) 2011; 5
Brouwer (R31-9-20210130) 2004; 363
French (R2-9-20210130) 2012; 196
Boulware (R20-9-20210130) 2010; 202
Anekthananon (R21-9-20210130) 2011; 22
References_xml – volume: 56
  start-page: 1165
  year: 2013
  ident: R8-9-20210130
  article-title: Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis.
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cit019
  contributor:
    fullname: Bisson
– volume: 49
  start-page: 931
  year: 2009
  ident: R38-9-20210130
  article-title: Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study.
  publication-title: Clin Infect Dis
  doi: 10.1086/605497
  contributor:
    fullname: Sungkanuparph
– volume: 50
  start-page: 1532
  year: 2010
  ident: R10-9-20210130
  article-title: Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-Saharan Africa.
  publication-title: Clin Infect Dis
  doi: 10.1086/652652
  contributor:
    fullname: Makadzange
– volume: 47
  start-page: 1556
  year: 2008
  ident: R37-9-20210130
  article-title: Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.
  publication-title: Clin Infect Dis
  doi: 10.1086/593194
  contributor:
    fullname: Longley
– volume: 196
  start-page: 318
  year: 2012
  ident: R2-9-20210130
  article-title: Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on.
  publication-title: Med J Aust
  doi: 10.5694/mja12.10089
  contributor:
    fullname: French
– volume: 19
  start-page: 1043
  year: 2005
  ident: R19-9-20210130
  article-title: Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France.
  publication-title: AIDS
  doi: 10.1097/01.aids.0000174450.70874.30
  contributor:
    fullname: Lortholary
– volume: 1
  start-page: 107
  year: 2000
  ident: R18-9-20210130
  article-title: Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.
  publication-title: HIV Med
  doi: 10.1046/j.1468-1293.2000.00012.x
  contributor:
    fullname: French
– volume: 51
  start-page: 130
  year: 2009
  ident: R24-9-20210130
  article-title: Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study.
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0b013e3181a56f2e
  contributor:
    fullname: Bicanic
– volume: 26
  start-page: 1105
  year: 2012
  ident: R35-9-20210130
  article-title: Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e3283536a93
  contributor:
    fullname: Jarvis
– volume: 42
  start-page: 1639
  year: 2006
  ident: R5-9-20210130
  article-title: Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy.
  publication-title: Clin Infect Dis
  doi: 10.1086/503903
  contributor:
    fullname: Robertson
– volume: 23
  start-page: 525
  year: 2009
  ident: R1-9-20210130
  article-title: Estimation of the current global burden of cryptococcal meningitis among persons living with HIVAIDS.
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e328322ffac
  contributor:
    fullname: Park
– volume: 5
  start-page: e10980
  year: 2010
  ident: R29-9-20210130
  article-title: Establishing the proteome of normal human cerebrospinal fluid.
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0010980
  contributor:
    fullname: Schutzer
– volume: 202
  start-page: 962
  year: 2010
  ident: R20-9-20210130
  article-title: Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome.
  publication-title: J Infect Dis
  doi: 10.1086/655785
  contributor:
    fullname: Boulware
– volume: 202
  start-page: 1728
  year: 2010
  ident: R27-9-20210130
  article-title: Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy.
  publication-title: J Infect Dis
  doi: 10.1086/657082
  contributor:
    fullname: Oliver
– volume: 48
  start-page: 1775
  year: 2009
  ident: R32-9-20210130
  article-title: A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.
  publication-title: Clin Infect Dis
  doi: 10.1086/599112
  contributor:
    fullname: Pappas
– volume: 46
  start-page: 1694
  year: 2008
  ident: R28-9-20210130
  article-title: Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy.
  publication-title: Clin Infect Dis
  doi: 10.1086/587667
  contributor:
    fullname: Kambugu
– volume: 52
  start-page: 1374
  year: 2011
  ident: R13-9-20210130
  article-title: Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cir230
  contributor:
    fullname: Torok
– volume: 254
  start-page: 114
  year: 2013
  ident: R26-9-20210130
  article-title: HIV and co-infections.
  publication-title: Immunol Rev
  doi: 10.1111/imr.12063
  contributor:
    fullname: Chang
– volume: 363
  start-page: 1764
  year: 2004
  ident: R31-9-20210130
  article-title: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.
  publication-title: Lancet
  doi: 10.1016/S0140-6736(04)16301-0
  contributor:
    fullname: Brouwer
– volume: 49
  start-page: 702
  year: 2009
  ident: R17-9-20210130
  article-title: Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients.
  publication-title: Clin Infect Dis
  doi: 10.1086/604716
  contributor:
    fullname: Bicanic
– volume: 18
  start-page: 1615
  year: 2004
  ident: R4-9-20210130
  article-title: Immune restoration disease after antiretroviral therapy.
  publication-title: AIDS
  doi: 10.1097/01.aids.0000131375.21070.06
  contributor:
    fullname: French
– volume: 365
  start-page: 1471
  year: 2011
  ident: R12-9-20210130
  article-title: Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1013911
  contributor:
    fullname: Blanc
– volume: 45
  start-page: 76
  year: 2007
  ident: R30-9-20210130
  article-title: Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole.
  publication-title: Clin Infect Dis
  doi: 10.1086/518607
  contributor:
    fullname: Bicanic
– volume: 5
  start-page: 252
  year: 2011
  ident: R16-9-20210130
  article-title: Cryptococcus-related immune reconstitution inflammatory syndrome (IRIS): pathogenesis and its clinical implications.
  publication-title: Curr Fungal Infect Rep
  doi: 10.1007/s12281-011-0064-8
  contributor:
    fullname: Wiesner
– volume: 10
  start-page: 251
  year: 2010
  ident: R3-9-20210130
  article-title: Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(10)70026-8
  contributor:
    fullname: Muller
– volume: 81
  start-page: 213
  year: 2002
  ident: R6-9-20210130
  article-title: Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.
  publication-title: Medicine (Baltimore)
  doi: 10.1097/00005792-200205000-00005
  contributor:
    fullname: Shelburne
– volume: 80
  start-page: 176
  year: 1974
  ident: R23-9-20210130
  article-title: Prognostic factors in cryptococcal meningitis. A study in 111 cases.
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-80-2-176
  contributor:
    fullname: Diamond
– volume: 22
  start-page: 665
  year: 2011
  ident: R21-9-20210130
  article-title: Predictors of poor clinical outcome of cryptococcal meningitis in HIV-infected patients.
  publication-title: Int J STD AIDS
  doi: 10.1258/ijsa.2011.010538
  contributor:
    fullname: Anekthananon
– volume: 50
  start-page: 291
  year: 2010
  ident: R33-9-20210130
  article-title: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America.
  publication-title: Clin Infect Dis
  doi: 10.1086/649858
  contributor:
    fullname: Perfect
– volume: 10
  start-page: 791
  year: 2010
  ident: R7-9-20210130
  article-title: Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions.
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(10)70170-5
  contributor:
    fullname: Haddow
– volume: 49
  start-page: 227
  year: 2008
  ident: R36-9-20210130
  article-title: The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana.
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0b013e318183181e
  contributor:
    fullname: Bisson
– volume: 365
  start-page: 1492
  year: 2011
  ident: R11-9-20210130
  article-title: Integration of antiretroviral therapy with tuberculosis treatment.
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1014181
  contributor:
    fullname: Abdool Karim
SSID ssj0005088
Score 2.4698062
Snippet HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination antiretroviral...
OBJECTIVEHIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination...
Objective: HIV-infected patients with treated cryptococcal meningitis are at risk for further neurological deterioration after commencing combination...
SourceID proquest
crossref
pubmed
pascalfrancis
SourceType Aggregation Database
Index Database
StartPage 2089
SubjectTerms Adult
AIDS/HIV
Anti-Retroviral Agents - administration & dosage
Antifungal Agents - administration & dosage
Biological and medical sciences
Biomarkers
CD4 Lymphocyte Count
Cerebrospinal Fluid - microbiology
Cohort Studies
Cryptococcosis - diagnosis
Cryptococcosis - pathology
Cryptococcus
Female
General aspects
HIV Infections - complications
HIV Infections - drug therapy
Human immunodeficiency virus
Human mycoses
Human viral diseases
Humans
Immune Reconstitution Inflammatory Syndrome - diagnosis
Immune Reconstitution Inflammatory Syndrome - pathology
Immunopathology
Infectious diseases
Longitudinal Studies
Male
Medical sciences
Miscellaneous mycoses
Mycoses
Prospective Studies
South Africa
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Title Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome
URI https://www.ncbi.nlm.nih.gov/pubmed/23525034
https://search.proquest.com/docview/1490705604
https://search.proquest.com/docview/1735923440
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2Mwxu7LLkWDvRVnnixb9qOXbks3OihroW9BvggCix1i56H7N_2n_WRZtlPSsu7FBDu2ZZ_P53w6OhdCPnKhWJhJgDdKfIcHPHLCUHr48NJIBh5Oy3Q28vGvYHbGf5z756PR5SBqaVMnk_TvzryS_5Eq9kGuOkv2DpLtLood-A35YgsJY_tPMp7atEbt_V5epJ0iW631-kvTSEeHja8vVnUJzZeW1aJyZCsRUM2Fzg7RjVPSsg0aMKGPCjhZmvX3XSUN4qPD38NeIJ0zYWrdz6ZmwaKQB9NJx5WBtkouG6nGSpfziLtj38vKxtt80R7KLK_rg6Pu8CCyRCd0QyfNJkN_he4dAaHxgVpjQeSAFLlDHWzqA1iseUON6poWQ6111pm-OzW_qSh8Eh9a1y54E6iHDLPe0tnV_WsGsAtLtAvyuMr8-lXukfsMukwr0Z8nfUF6zW-NG888lM3OjMSnXWPZYj-PVrICJpTpoHLzFKehOqdPyON2jkJjA7inZJQXz8iD4zYK4zn5Y3FHgTs6wB3tcUdLRW_EHTW4o9u4o0PcUYu7F-Ts29fT6cxpu3Y4KQ9Z7SQ61RtmS2Gqn0vwIxbmAablPliQaLxnEROBTIVSifSDTOZ56nlMZb5kCsrBe0n2irLIXxP62ZdBEElQYrBQP3HDhKWhyESSuB5zfTkmjn2b85UpzjK_TYZjsr_1yruTMCABQyvG5IOVwRxqVq-dySIvNxVmyBGMI6YH_Jb_CDw68zh3x-SVEWB_B1122PX4mzsO-S152H9E78hevd7k70GD62S_AeIVL6eyyA
link.rule.ids 315,783,787,27936,27937
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+and+mycological+predictors+of+cryptococcosis-associated+immune+reconstitution+inflammatory+syndrome&rft.jtitle=AIDS+%28London%29&rft.au=Chang%2C+Christina+C.&rft.au=Dorasamy%2C+Afton+A.&rft.au=Gosnell%2C+Bernadett+I.&rft.au=Elliott%2C+Julian+H.&rft.date=2013-08-24&rft.issn=0269-9370&rft.volume=27&rft.issue=13&rft.spage=2089&rft.epage=2099&rft_id=info:doi/10.1097%2FQAD.0b013e3283614a8d&rft.externalDBID=n%2Fa&rft.externalDocID=10_1097_QAD_0b013e3283614a8d
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-9370&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-9370&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-9370&client=summon